Frontlight ResearchEarly access
TerminatedPhase 2
Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients
Key facts
- Who runs it
- Universitair Ziekenhuis Brussel
- Where
- Belgium1 site in 1 countryChoose a country to see its sites
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 7 people enrolled
- Started
- 16 Oct 2017
- Ended
- 14 Oct 2025
- Type of study
- Interventional
- Treatments tested
- 68GaNOTA-Anti-HER2 VHH1
- Record updated
- 1 June 2026
- Why it stopped
- Delay in recruitment
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patients who have given informed consent
- Age 18 years or older
- Patients with brain metastasized cancer, with at least 1 brain lesion of at least 8 mm maximal diameter, as measured by CT or MRI
- Patients with potentially HER2-positive cancer. Either a HER2 staining should have been done in standard of care, or sufficient tissue should be available for HER2-staining for study purpose
Who cannot take part
- Patients at increased risk of death from a pre-existing concurrent illness
- Patients with recent (< 1 week) gastrointestinal disorders with diarrhea as major symptom
- Patients with any serious active infection
- Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the test radiopharmaceutical
- Pregnant patients
- Breast feeding patients
- Patients who cannot communicate reliably with the investigator
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study investigates the uptake of the radiopharmaceutical 68-GaNOTA-Anti-HER2 VHH1 in brain metastasis using PET/CT imaging. Patients with HER2-positive and HER2-negative cancer will be included and the uptake in their lesions will be compared.
Read full original descriptionShow less
Optional 68-GaNOTA-Anti-HER2 VHH1 scans may be performed during or after treatment, at time points 12±6 weeks and 24±9 weeks after the first scan.
Treatments tested
- 68GaNOTA-Anti-HER2 VHH1
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- Evaluation of 68GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients
- Record updated
- 1 June 2026